Glycocalyx as Possible Limiting Factor in COVID-19.

Wadowski, Patricia P; Jilma, Bernd; Kopp, Christoph W; Ertl, Sebastian; Gremmel, Thomas; Koppensteiner, Renate

Wadowski, Patricia P; Jilma, Bernd; Kopp, Christoph W; Ertl, Sebastian; Gremmel, Thomas; Koppensteiner, Renate.

Afiliação

Wadowski PP; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Kopp CW; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Ertl S; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Gremmel T; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Koppensteiner R; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Front Immunol ; 12: 607306, 2021.

Article em En | MEDLINE | ID: mdl-33692785

Assuntos

COVID-19/virologia; Glicocálix/virologia; SARS-CoV-2/patogenicidade; COVID-19/metabolismo; COVID-19/patologia; Endotélio/patologia; Endotélio/virologia; Glicocálix/metabolismo; Glicocálix/patologia; Heparitina Sulfato/metabolismo; Humanos

Palavras-chave

COVID-19; SARS-CoV-2; complement; glycocalyx; heparan sulfate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glicocálix / SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google